DoubleChecks

What was claimed

A 70-year-old man with stage 4 pancreatic cancer (given months to live) improved dramatically with CA19-9 markers dropping after self-treating with Ivermectin (1.5 mg/kg/day), Fenbendazole (1,500 mg/day), and CBD oil (100 mg/day); oncologists demanded he stop because they couldn't explain it.

Our verdict

Inaccurate

No clinical trials on ivermectin, fenbendazole, or mebendazole for pancreatic cancer have been completed. CBD evidence remains preclinical with insufficient clinical evidence. ASCO recommended against these treatments outside clinical trials as of May 2026. Evidence suggests these agents should only be used alongside standard oncology, never in place of it. Taking them while avoiding proven treatments could make outcomes worse and worsen side effects.

0 of 3 AI systems agree15 sources citedChecked Aug 31, 2026

Check your own claim

Paste any statement, headline, or AI answer — 3 independent AIs verify it in seconds, with sources.

Key findings

These treatments work as monotherapy for stage 4 pancreatic cancer

Incorrect90%
1 AI checked

Ivermectin, Fenbendazole, and CBD oil are established treatments for stage 4 pancreatic cancer

Incorrect95%
1 AI checked

CA19-9 marker decline indicates cancer improvement

Misleading80%
1 AI checked

Oncologists demanded he stop because they couldn't explain the improvement

Misleading85%
1 AI checked

A 70-year-old man with stage 4 pancreatic cancer (given months to live) improved dramatically with CA19-9 markers dropping after self-treating with Ivermectin (1.5 mg/kg/day), Fenbendazole (1,500 mg/day), and CBD oil (100 mg/day); oncologists demanded he stop because they couldn't explain it.

Can’t verify57%
2 of 4 AIs agree·ChatGPT: Misleading, Perplexity: Misleading

Verified against 15 sources

onedaymd.comonedaymd.substack.comonedaymd.substack.compmc.ncbi.nlm.nih.govoncodaily.com2ndsmartestguyintheworld.comx.comsmartcancer.orgtruth613.substack.comahbps.orgnote.comwebmd.comreddit.comsanarelab.sciencear.iiarjournals.org

Detailed Analysis

The core story closely matches a recent online testimonial, but it is anecdotal and not independently verified by medical literature or mainstream news. The dosing details and CA19-9 improvement are consistent with that testimonial, yet the claim that oncologists demanded he stop because they could not explain it is not corroborated by reliable sources.

Why this verdict

  • The core story closely matches a recent online testimonial, but it is anecdotal and not independently verified by medical literature or mainstream news.
  • The dosing details and CA19-9 improvement are consistent with that testimonial, yet the claim that oncologists demanded he stop because they could not explain it is not corroborated by reliable sources.

Claims checked

A 70-year-old man with stage 4 pancreatic cancer (given months to live) improved dramatically with CA19-9 markers dropping after self-treating with Ivermectin (1.5 mg/kg/day), Fenbendazole (1,500 mg/day), and CBD oil (100 mg/day).

Misleading78%
A July 2026 testimonial by William Makis describes a 70‑year‑old Manitoba man with stage 4 pancreatic cancer using ivermectin 1.5 mg/kg, fenbendazole 1500 mg, and CBD oil 100 mg, with reported CA19‑9 reduction, which matches this description. However, this is a self-published anecdote without independent clinical verification, and mainstream medical sources stress there is no proven human clinical efficacy of ivermectin or fenbendazole in pancreatic cancer, so presenting it as a factual medical outcome is misleading.

This claim may mislead readers without added context.

Oncologists demanded he stop because they couldn’t explain it.

Can’t verify55%
The testimonial mentions that Canadian oncologists were baffled or shocked, but does not provide verifiable documentation or direct quotes confirming that oncologists explicitly demanded he stop due to being unable to explain the results. This specific behavior and motivation of the oncologists cannot be confirmed from independent, authoritative sources.

What other AI think

The statement mixes anecdotal reports with unverified clinical claims. While some case reports exist describing CA19-9 declines with these treatments, no clinical trials have established efficacy, and the claim that "oncologists demanded he stop because they couldn't explain it" is a narrative framing that misrepresents standard medical caution about unproven treatments.

Why this verdict

  • The statement mixes anecdotal reports with unverified clinical claims.
  • While some case reports exist describing CA19-9 declines with these treatments, no clinical trials have established efficacy, and the claim that "oncologists demanded he stop because they couldn't explain it" is a narrative framing that misrepresents standard medical caution about unproven treatments.

Claims checked

These treatments work as monotherapy for stage 4 pancreatic cancer

Incorrect90%
Evidence suggests these agents should only be used alongside standard oncology, never in place of it. Taking them while avoiding proven treatments could make outcomes worse and worsen side effects.

This claim may mislead readers without added context.

Ivermectin, Fenbendazole, and CBD oil are established treatments for stage 4 pancreatic cancer

Incorrect95%
No clinical trials on ivermectin, fenbendazole, or mebendazole for pancreatic cancer have been completed. CBD evidence remains preclinical with insufficient clinical evidence. ASCO recommended against these treatments outside clinical trials as of May 2026.

This claim may mislead readers without added context.

CA19-9 marker decline indicates cancer improvement

Misleading80%
CA19-9 decline can indicate improvement, but the marker has significant limitations: false positives in benign conditions, false negatives in Lewis-negative individuals, and can fluctuate without clinical significance. Imaging confirmation is needed to confirm actual tumor response.

This claim may mislead readers without added context.

The statement is based on anecdotal reports and online testimonials rather than peer-reviewed clinical evidence. Dosing given (ivermectin 1.5 mg/kg/day and fenbendazole 1,500 mg/day) is not standard or supported by approved human-treatment guidelines, and the causal link between those drugs and dramatic CA19-9 drops is unverified.

Why this verdict

  • The statement is based on anecdotal reports and online testimonials rather than peer-reviewed clinical evidence.
  • Dosing given (ivermectin 1.5 mg/kg/day and fenbendazole 1,500 mg/day) is not standard or supported by approved human-treatment guidelines, and the causal link between those drugs and dramatic CA19-9 drops is unverified.

Claims checked

A 70-year-old man with stage 4 pancreatic cancer (given months to live) improved dramatically with CA19-9 markers dropping after self-treating with Ivermectin (1.5 mg/kg/day), Fenbendazole (1,500 mg/day), and CBD oil (100 mg/day); oncologists demanded he stop because they couldn't explain it.

Misleading80%
I found only anecdotal reports, social-media posts, and compilations of testimonials describing similar stories, not verified medical case reports or peer-reviewed evidence that confirm this specific claim or prove causation. The ivermectin dose cited (1.5 mg/kg/day) is much higher than usual approved single-dose regimens (~0.2 mg/kg), and fenbendazole has no established human anticancer dosing or regulatory approval, so the safety and causality are unproven.

This claim may mislead readers without added context.

Share this result

Try DoubleChecks